Technology evaluation: EPI-2010, EpiGenesis.
EpiGenesis, in collaboration with Taisho and Chiesi, is developing EPI-2010, a 21-mer phosphorothioate respirable antisense oligonucleotide (RASON) that blocks the synthesis of the adenosine A1 receptor, for the potential treatment of asthma.
EPIX Medical Inc, Cambridge, MA 02142-1118, USA. zzhang@epixmed.com
Zhaoda
Z
Zhang
D000280:Administration, Inhalation; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004195:Disease Models, Animal; D006801:Humans; D020319:Oligodeoxyribonucleotides, Antisense / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D010710:Phosphates / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D012120:Respiration Disorders / Q000188:drug therapy* / Q000517:prevention & control; D013329:Structure-Activity Relationship
D018927:Anti-Asthmatic Agents; C425883:EPI2010; D020319:Oligodeoxyribonucleotides, Antisense; D010710:Phosphates